464 related articles for article (PubMed ID: 34259953)
21. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Database.
Okuma Y; Shintani Y; Sekine I; Shukuya T; Takayama K; Inoue A; Okamoto I; Kiura K; Yamamoto N; Kawaguchi T; Miyaoka E; Yoshino I; Date H
Clin Lung Cancer; 2024 Jun; 25(4):336-346.e2. PubMed ID: 38360497
[TBL] [Abstract][Full Text] [Related]
23. The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer institute.
Yan W; Jing W; An N; Tian Y; Guo D; Kong L; Zhu H; Yu J
Cancer Med; 2019 Jun; 8(6):2769-2776. PubMed ID: 30993909
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations.
Yamada Y; Imai H; Sugiyama T; Minemura H; Kanazawa K; Kasai T; Minato K; Kaira K; Kaburagi T
Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577852
[No Abstract] [Full Text] [Related]
25. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.
Kawamura T; Hata A; Takeshita J; Fujita S; Hayashi M; Tomii K; Katakami N
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1261-6. PubMed ID: 25921002
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
[TBL] [Abstract][Full Text] [Related]
27. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
28. Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor.
Kwon BS; Cho YH; Yoon SK; Lee DH; Kim SW; Kwon DH; Lee JC; Choi CM
Thorac Cancer; 2020 Feb; 11(2):436-442. PubMed ID: 31910497
[TBL] [Abstract][Full Text] [Related]
29. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Yu X; Sheng J; Pan G; Fan Y
Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.
Hoffknecht P; Tufman A; Wehler T; Pelzer T; Wiewrodt R; Schütz M; Serke M; Stöhlmacher-Williams J; Märten A; Maria Huber R; Dickgreber NJ;
J Thorac Oncol; 2015 Jan; 10(1):156-63. PubMed ID: 25247337
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial.
Fan C; Jiang Z; Teng C; Song X; Li L; Shen W; Jiang Q; Huang D; Lv Y; Du L; Wang G; Hu Y; Man S; Zhang Z; Gao N; Wang F; Shi T; Xin T
ESMO Open; 2024 Apr; 9(4):102384. PubMed ID: 38377785
[TBL] [Abstract][Full Text] [Related]
32. [Epidermal growth factor tyrosine kinase inhibitors used in the treatment of NSCLC patients with leptomeningeal metastasis].
Xu Y; Zhong W; Zhao J; Chen MJ; Zhang L; Li LY; Wang MZ
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):920-924. PubMed ID: 27998469
[No Abstract] [Full Text] [Related]
33. Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
Yang H; Wen L; Pan Y; Shan C; Hong W; Wang H; Zhou C; Cai L; Zhou C
BMC Cancer; 2022 May; 22(1):580. PubMed ID: 35614407
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
35. Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations.
Li YS; Jiang BY; Yang JJ; Tu HY; Zhou Q; Guo WB; Yan HH; Wu YL
J Thorac Oncol; 2016 Nov; 11(11):1962-1969. PubMed ID: 27539328
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.
Cappuzzo F; Morabito A; Normanno N; Bidoli P; Del Conte A; Giannetta L; Montanino A; Mazzoni F; Buosi R; Burgio MA; Cerea G; Chiari R; Cortinovis D; Finocchiaro G; Foltran L; Migliorino MR; Tiseo M; Ferrari S; De Marinis F
Lung Cancer; 2016 Sep; 99():31-7. PubMed ID: 27565910
[TBL] [Abstract][Full Text] [Related]
37. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.
Yang JCH; Kim SW; Kim DW; Lee JS; Cho BC; Ahn JS; Lee DH; Kim TM; Goldman JW; Natale RB; Brown AP; Collins B; Chmielecki J; Vishwanathan K; Mendoza-Naranjo A; Ahn MJ
J Clin Oncol; 2020 Feb; 38(6):538-547. PubMed ID: 31809241
[TBL] [Abstract][Full Text] [Related]
38. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
39. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis.
Liao BC; Lee JH; Lin CC; Chen YF; Chang CH; Ho CC; Shih JY; Yu CJ; Yang JC
J Thorac Oncol; 2015 Dec; 10(12):1754-61. PubMed ID: 26334749
[TBL] [Abstract][Full Text] [Related]
40. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]